Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
A Phase I Study to Characterize the Tolerance, Safety, Pharmacokinetics/Pharmacodynamics and Effect of PD-1 Inhibitor SHR-1210 in Combination With IDO Inhibitor SHR9146 and With/Without Apatinib in Patients With Advanced Solid Tumors (PIANO)
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This PHASE1 trial investigates Cancer, Metastatic and Neoplasm Malignant and is currently ongoing. Jiangsu HengRui Medicine Co., Ltd. leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Dec 2024 — Present [monthly]
Unknown PHASE1
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Jan 2021 — Dec 2022 [monthly]
Unknown Status PHASE1
▶ Show 3 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
-
Jul 2018 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .